Information
Address

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Switchboard:

Switchboard

+33 (0)1 42 11 42 11

GUSTAVE ROUSSY
1st cancer center in Europe

© 2006-2015 Gustave Roussy – All rights reserved

06/28/2019

ONCOBIOME, 1st consortium about microbiome & cancer, led by Gustave Roussy

Gustave Roussy, leading European Cancer Centre, is collaborating with 16 international partners in the Oncobiome consortium. The objective of the programme is to determine the relationship between intestinal microbial signatures (GOMS) and the incidence, prognosis and resistance to treatment (and toxicity of this) in cancers of breast, colon, lung...
06/28/2019

ONCOBIOME, 1er programme européen consacré aux liens entre microbiome et cancer

Gustave Roussy s’associe à 16 partenaires internationaux au sein du consortium ONCOBIOME, dont l'objectif est d’identifier les signatures microbiennes intestinales (GOMS) associées à l'incidence, au pronostic ainsi qu’à la résistance au traitement et à leur toxicité dans les cancers du sein, du colon, du poumon et du mélanome. 

Les équipes de...

Microbiome & cancer: the ONCOBIOME consortium led by Gustave Roussy has obtained 15 m€ from Europe

back to job offer list
back to clinical trials

Villejuif, 27 june 2019

Microbiome & cancer:
the ONCOBIOME consortium led by Gustave Roussy has obtained 15 m€ from Europe

ONCOBIOME

Gustave Roussy reaffirms its commitment to research integrity

back to job offer list
back to clinical trials

Villejuif, 18 june 2019

Gustave Roussy reaffirms its commitment to research integrity

On Thursday 13 June, Prof. Eric Solary, Director of Research at Gustave Roussy, signed up to the French Charter for Research Integrity on behalf of the Institute, in the presence of Joëlle Alnot, Director of the French Office for Research Integrity (Ofis).

06/14/2019

Gustave Roussy, leading centre of immunotherapy in Europe

Immunotherapy boosts the immune system to fight cancer cells. Gustave Roussy is a pionner in immunotherapy and the largest tratment facility in Europe. Between 2013 and 2018, 241 immunotherapy-based clinical trials were implemented at the Insitute and 3,317 patients have been treated with immunotherapy. 

By their participation in the initial...

Evaluation de la réintroduction d’une immunothérapie anti-PD-1 chez des patients atteints de cancers après arrêt du traitement pour toxicité aigüe

back to job offer list
back to clinical trials

Le 11 juin 2019

ASCO 2019 - Melanoma: The advantages of targeted dual therapy confirmed at five years

back to job offer list
back to clinical trials

Chicago, 4th June 2019
ASCO 2019

ASCO 2019 - Urothelial cancer (bladder and urinary tract): new evidence of the value of immunotherapy

back to job offer list
back to clinical trials

Chicago, 3 June 2019
ASCO 2019

Urothelial cancer (bladder and urinary tract)
New evidence of the value of immunotherapy

Urothelial cancer, usually developing in the bladder, is common and serious. Its management is complex. It accounts for 90% of bladder cancers. With 12,000 new cases diagnosed each year in France, bladder cancer is the urological cancer encountered most frequently after prostate cancer.

ASCO 2019 - Larotrectinib, first targeted therapy for childhood solid tumours, shown to be effective

back to job offer list
back to clinical trials

Chicago, 3 june 2019
ASCO 2019

ASCO 2019
05/31/2019

Gustave Roussy at ASCO 2019

As every year for almost 55 years, the world’s leading cancer experts will meet in Chicago to talk about the latest advances in clinical oncology at the international meeting of the American Society of Clinical Oncology (ASCO).

Pages